Equity Details
Price & Market Data
Price: $1.47
Daily Change: -$0.01 / 0.68%
Daily Range: $1.44 - $1.52
Market Cap: $497,627,136
Daily Volume: 6,725,167
Performance Metrics
1 Week: -1.34%
1 Month: -17.88%
3 Months: 3.52%
6 Months: 8.09%
1 Year: 110.0%
YTD: 8.89%
About Ocugen, Inc. (OCGN)
Up-to-the-minute market analysis for Ocugen, Inc. (OCGN). Current price: 1.47, daily change: -$0.01 / 0.68%. Market cap: 497,627,136. Explore all available performance indicators.
Company Details
Employees: 116
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.